HUMANIGEN INC (HGEN) Fundamental Analysis & Valuation

NASDAQ:HGEN • US4448632038

Current stock price

0.0361 USD
-0.16 (-81.12%)
At close:
0.0358 USD
0 (-0.83%)
After Hours:

This HGEN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. HGEN Profitability Analysis

1.1 Basic Checks

  • In the past year HGEN has reported negative net income.
  • HGEN had a negative operating cash flow in the past year.
HGEN Yearly Net Income VS EBIT VS OCF VS FCFHGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -50M -100M -150M -200M

1.2 Ratios

  • The profitability ratios for HGEN are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HGEN Yearly ROA, ROE, ROICHGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 5K -5K 10K 15K

1.3 Margins

  • HGEN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HGEN Yearly Profit, Operating, Gross MarginsHGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 -5K -10K -15K -20K -25K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. HGEN Health Analysis

2.1 Basic Checks

  • HGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for HGEN has been increased compared to 1 year ago.
  • HGEN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
HGEN Yearly Shares OutstandingHGEN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
HGEN Yearly Total Debt VS Total AssetsHGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -232.21, we must say that HGEN is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -232.21, HGEN is doing worse than 99.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -232.21
ROIC/WACCN/A
WACC11.19%
HGEN Yearly LT Debt VS Equity VS FCFHGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 -50M -100M -150M

2.3 Liquidity

  • HGEN has a Current Ratio of 0.09. This is a bad value and indicates that HGEN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • HGEN has a worse Current ratio (0.09) than 99.66% of its industry peers.
  • A Quick Ratio of 0.09 indicates that HGEN may have some problems paying its short term obligations.
  • HGEN has a Quick ratio of 0.09. This is amonst the worse of the industry: HGEN underperforms 99.66% of its industry peers.
Industry RankSector Rank
Current Ratio 0.09
Quick Ratio 0.09
HGEN Yearly Current Assets VS Current LiabilitesHGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. HGEN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 79.50% over the past year.
  • HGEN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -59.01%.
EPS 1Y (TTM)79.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.5%
Revenue 1Y (TTM)-59.01%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-78.67%

3.2 Future

  • HGEN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.74% yearly.
  • HGEN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 110.13% yearly.
EPS Next Y83.55%
EPS Next 2Y37.89%
EPS Next 3Y27.81%
EPS Next 5Y15.74%
Revenue Next Year-91.42%
Revenue Next 2Y-41.42%
Revenue Next 3Y165.44%
Revenue Next 5Y110.13%

3.3 Evolution

HGEN Yearly Revenue VS EstimatesHGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
HGEN Yearly EPS VS EstimatesHGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

1

4. HGEN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for HGEN. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HGEN Price Earnings VS Forward Price EarningsHGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HGEN Per share dataHGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • HGEN's earnings are expected to grow with 27.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.89%
EPS Next 3Y27.81%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HGEN Dividend Analysis

5.1 Amount

  • No dividends for HGEN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

HGEN Fundamentals: All Metrics, Ratios and Statistics

HUMANIGEN INC

NASDAQ:HGEN (7/25/2023, 8:00:02 PM)

After market: 0.0358 0 (-0.83%)

0.0361

-0.16 (-81.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15
Earnings (Next)08-10
Inst Owners0.01%
Inst Owner Change0%
Ins Owners5.13%
Ins Owner Change0%
Market Cap4.30M
Revenue(TTM)1.70M
Net Income(TTM)-53.63M
Analysts43.33
Price Target0.15 (315.51%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)106.85%
Min EPS beat(2)34.64%
Max EPS beat(2)179.06%
EPS beat(4)2
Avg EPS beat(4)36.56%
Min EPS beat(4)-42.54%
Max EPS beat(4)179.06%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)116.67%
Min Revenue beat(2)116.67%
Max Revenue beat(2)116.67%
Revenue beat(4)2
Avg Revenue beat(4)51.22%
Min Revenue beat(4)-58.33%
Max Revenue beat(4)116.67%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-53.85%
PT rev (3m)-53.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)33.33%
EPS NY rev (1m)41.75%
EPS NY rev (3m)41.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.53
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.65
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS0.01
BVpS-0.42
TBVpS-0.42
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.09
Quick Ratio 0.09
Altman-Z -232.21
F-Score3
WACC11.19%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.5%
EPS Next Y83.55%
EPS Next 2Y37.89%
EPS Next 3Y27.81%
EPS Next 5Y15.74%
Revenue 1Y (TTM)-59.01%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-78.67%
Revenue Next Year-91.42%
Revenue Next 2Y-41.42%
Revenue Next 3Y165.44%
Revenue Next 5Y110.13%
EBIT growth 1Y72.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year62.92%
EBIT Next 3Y21.33%
EBIT Next 5Y-8.13%
FCF growth 1Y38.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.78%
OCF growth 3YN/A
OCF growth 5YN/A

HUMANIGEN INC / HGEN Fundamental Analysis FAQ

What is the fundamental rating for HGEN stock?

ChartMill assigns a fundamental rating of 1 / 10 to HGEN.


Can you provide the valuation status for HUMANIGEN INC?

ChartMill assigns a valuation rating of 1 / 10 to HUMANIGEN INC (HGEN). This can be considered as Overvalued.


What is the profitability of HGEN stock?

HUMANIGEN INC (HGEN) has a profitability rating of 0 / 10.


What is the earnings growth outlook for HUMANIGEN INC?

The Earnings per Share (EPS) of HUMANIGEN INC (HGEN) is expected to grow by 83.55% in the next year.